JP2025509152A - 抗ＣａｎＡｇ抗体複合体 - Google Patents
抗ＣａｎＡｇ抗体複合体 Download PDFInfo
- Publication number
- JP2025509152A JP2025509152A JP2024552013A JP2024552013A JP2025509152A JP 2025509152 A JP2025509152 A JP 2025509152A JP 2024552013 A JP2024552013 A JP 2024552013A JP 2024552013 A JP2024552013 A JP 2024552013A JP 2025509152 A JP2025509152 A JP 2025509152A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- adc
- antibody
- formula
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2203070.4A GB202203070D0 (en) | 2022-03-04 | 2022-03-04 | Anti-canag antibody conjugate |
| GB2203070.4 | 2022-03-04 | ||
| PCT/GB2023/050522 WO2023166322A1 (en) | 2022-03-04 | 2023-03-06 | Anti-canag antibody conjugate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025509152A true JP2025509152A (ja) | 2025-04-11 |
| JP2025509152A5 JP2025509152A5 (https=) | 2026-01-26 |
| JPWO2023166322A5 JPWO2023166322A5 (https=) | 2026-01-26 |
Family
ID=81175257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552013A Pending JP2025509152A (ja) | 2022-03-04 | 2023-03-06 | 抗ＣａｎＡｇ抗体複合体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250213711A1 (https=) |
| EP (1) | EP4486392A1 (https=) |
| JP (1) | JP2025509152A (https=) |
| KR (1) | KR20240163656A (https=) |
| CN (1) | CN119136841A (https=) |
| AU (1) | AU2023229192A1 (https=) |
| GB (1) | GB202203070D0 (https=) |
| IL (1) | IL315428A (https=) |
| WO (1) | WO2023166322A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| GB202313214D0 (en) * | 2023-08-30 | 2023-10-11 | Iksuda Therapeutics Ltd | Co-administration of antibody-drug conjugate |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE045348T2 (hu) | 2011-05-08 | 2019-12-30 | Legochem Biosciences Inc | Fehérje-hatóanyag konjugátumok és eljárás elõállításukra |
| KR101628872B1 (ko) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
| HRP20240795T1 (hr) | 2015-11-25 | 2024-09-13 | Ligachem Biosciences Inc. | Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima |
| KR102847350B1 (ko) | 2015-11-25 | 2025-08-19 | 주식회사 리가켐바이오사이언스 | 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법 |
| MX2019011655A (es) * | 2017-03-29 | 2019-12-19 | Legochem Biosciences Inc | Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este. |
| WO2018182341A1 (ko) | 2017-03-29 | 2018-10-04 | 주식회사 레고켐 바이오사이언스 | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 |
| EP3950061A4 (en) * | 2019-03-25 | 2022-11-16 | Daiichi Sankyo Company, Limited | ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE |
-
2022
- 2022-03-04 GB GBGB2203070.4A patent/GB202203070D0/en not_active Ceased
-
2023
- 2023-03-06 US US18/843,659 patent/US20250213711A1/en active Pending
- 2023-03-06 WO PCT/GB2023/050522 patent/WO2023166322A1/en not_active Ceased
- 2023-03-06 IL IL315428A patent/IL315428A/en unknown
- 2023-03-06 EP EP23711533.2A patent/EP4486392A1/en active Pending
- 2023-03-06 AU AU2023229192A patent/AU2023229192A1/en active Pending
- 2023-03-06 CN CN202380037771.5A patent/CN119136841A/zh active Pending
- 2023-03-06 JP JP2024552013A patent/JP2025509152A/ja active Pending
- 2023-03-06 KR KR1020247032787A patent/KR20240163656A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023229192A1 (en) | 2024-09-12 |
| EP4486392A1 (en) | 2025-01-08 |
| IL315428A (en) | 2024-11-01 |
| KR20240163656A (ko) | 2024-11-19 |
| WO2023166322A1 (en) | 2023-09-07 |
| US20250213711A1 (en) | 2025-07-03 |
| CN119136841A (zh) | 2024-12-13 |
| GB202203070D0 (en) | 2022-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7254861B2 (ja) | エリブリンをベースとする抗体－薬物コンジュゲート及び使用方法 | |
| JP7158548B2 (ja) | Ｍｕｃ１に特異的に結合する抗体及びその用途 | |
| CA3093327C (en) | Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof | |
| CN105980411B (zh) | 抗体-药物缀合物和免疫毒素 | |
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| JP2025509152A (ja) | 抗ＣａｎＡｇ抗体複合体 | |
| CN105979971B (zh) | 抗体-药物缀合物和免疫毒素 | |
| US10562977B2 (en) | Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof | |
| TW202203978A (zh) | 電荷可變連接子 | |
| AU2019272250A1 (en) | Anti-mesothelin antibody and antibody-drug conjugate thereof | |
| JP2023515845A (ja) | 抗－ｃｄ５６抗体－薬物複合体およびその治療での使用 | |
| JP2022519273A (ja) | 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート | |
| AU2015340370A9 (en) | Materials and methods relating to linkers for use in protein drug conjugates | |
| KR20250137203A (ko) | 항체 약물 접합체 | |
| JP2019524845A (ja) | セコ−シクロプロパピロロインドール化合物、その抗体−薬物コンジュゲート、ならびに製造および使用方法 | |
| KR20170139110A (ko) | 칼리케아마이신 구성체 및 사용 방법 | |
| JP2020532543A (ja) | 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用 | |
| WO2025046218A1 (en) | Co-administration of antibody-drug conjugate | |
| WO2024013520A1 (en) | Folate receptor targeting antibody-drug conjugates | |
| WO2026082125A1 (zh) | 结合folr1的抗体、含有其的药物及其应用 | |
| BR112016018005B1 (pt) | Conjugados anticorpo-droga e imunotoxinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241022 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260115 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260115 |